| Autor: |
Ségolène Turquier, Jean-François Cordier, François Philit, Julie Traclet, Marylise Ginoux, Chahéra Khouatra, Jean-François Mornex, Agathe Sénéchal, Vincent Cottin, Jean-Charles Glerant |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
4.3 Pulmonary Circulation and Pulmonary Vascular Diseases. |
| DOI: |
10.1183/13993003.congress-2016.pa2406 |
| Popis: |
Introduction: Age of the patients at diagnosis of pulmonary arterial hypertension (PAH) is steadily increasing. Elderly patients are rarely included in clinical trials and there are no specific studies on this population. The present study sought to analyze the current management of the elderly and very elderly patients and assessed their therapeutic response and tolerance. Methods: A single-center retrospective study was conducted in a regional referral center for PAH. All consecutive patients, diagnosed with PAH in the study period were included and grouped for age as Results: Between November 1, 2010 and October 31, 2014, 113 patients were included: 56 (49.6%) aged p =0.879) but 65-74 years and ≥75 years received less often upfront combination therapy (respectively 35.7%, 20.8% and 6.1%; p =0.047). At 3-6 months, there was a significant improvement in NYHA functional class, pulmonary vascular resistance (PVR) and in cardiac output (CO) in p all p =0.027). The occurrence of adverse events was more frequent with phosphodiesterase-5 inhibitors ( p =0.009) and endothelin receptor antagonists ( p =0.004) in patients ≥75 years than in younger subjects. Conclusions: Very elderly patients have a response and safety profile to PAH treatment less favourable than younger patients. The clinical and hemodynamic benefit seems to be reduced, and the risk of adverse effects may be more frequent. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
